Arde­lyx chops a third of its staff af­ter stock-crush­ing fail­ure in chron­ic kid­ney dis­ease

A cou­ple of weeks af­ter the FDA turned down Arde­lyx’s chron­ic kid­ney dis­ease can­di­date, shock­ing an­a­lysts and CEO Mike Raab, the com­pa­ny is ax­ing 33% of its em­ploy­ees to deal with the loss.

Arde­lyx shared in an SEC fil­ing it’s cut­ting 83 em­ploy­ees in a re­struc­tur­ing plan that will be im­ple­ment­ed this month. The plan is ex­pect­ed to save the com­pa­ny about $17 mil­lion in cash com­pen­sa­tion an­nu­al­ly, ac­cord­ing to the fil­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER